Bonraybio Co., Ltd. (6955.TWO)
TWD 141.5
(N/A%)
TWD 141.5
(N/A%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | 26.89 Million | 11.98 Million | -25.09 Million | -22.87 Million |
| Net Income | 25.75 Million | 1.71 Million | -31.69 Million | -41.17 Million |
| Depreciation & Amortization | 10.64 Million | 9.5 Million | 11.25 Million | 12.42 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | 82 Thousand | 515 Thousand | 789 Thousand |
| Change in working capital | -9 Million | 1.38 Million | -2.13 Million | 4.46 Million |
| Other non-cash items | -3.29 Million | -1.3 Million | -4.77 Million | -206 Thousand |
| Investing Cash Flow | 3.7 Million | -4.04 Million | -76.69 Million | -63.7 Million |
| Investments in PPE | -9.75 Million | -7.95 Million | -4.64 Million | -5.91 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | -73.43 Million | -58.1 Million |
| Sales/Maturities of investments | 9.8 Million | 4.14 Million | - | 310 Thousand |
| Other Investing Activities | 3.65 Million | -228 Thousand | 1.38 Million | - |
| Financing Cash Flow | -3.03 Million | 10.9 Million | 161.85 Million | -2.51 Million |
| Debt repayment | - | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | 13.77 Million | 164.58 Million | 198 Thousand |
| Other Financing Activities | -3.03 Million | - | - | - |
| Accounts receivables | -9.36 Million | - | - | - |
| Accounts payables | - | - | - | - |
| Inventory | -2.58 Million | -2.88 Million | -893 Thousand | -3.24 Million |
| Other working capital | 2.95 Million | - | - | - |
| Cash at beginning of period | 89.41 Million | 70.01 Million | 10.72 Million | 100.52 Million |
| Cash at end of period | 116.87 Million | 89.41 Million | 70.01 Million | 10.72 Million |
| Capital Expenditure | -9.75 Million | -7.95 Million | -4.64 Million | -5.91 Million |
| Effect of forex changes on cash | -110 Thousand | 553 Thousand | -773 Thousand | -704 Thousand |
| Net cash flow / Change in cash | 27.45 Million | 19.4 Million | 59.29 Million | -89.8 Million |
| Free Cash Flow | 17.14 Million | 4.02 Million | -29.73 Million | -28.78 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 16.49 Million | 14.26 Million | 25.75 Million | 3.21 Million | 2.85 Million | 1.71 Million |
| Depreciation & Amortization | 2.94 Million | 2.99 Million | 10.64 Million | 2.66 Million | 2.52 Million | 9.5 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | 82 Thousand |
| Change in working capital | -6.51 Million | 941 Thousand | -9 Million | 323 Thousand | -13 Million | 1.38 Million |
| Other non-cash items | -1.05 Million | -666 Thousand | -3.29 Million | -919 Thousand | -812 Thousand | -1.3 Million |
| Investing Cash Flow | -5.11 Million | -1.78 Million | 3.7 Million | -1.44 Million | 6.52 Million | -4.04 Million |
| Investments in PPE | -4.69 Million | -1.78 Million | -9.75 Million | -1.45 Million | -3.28 Million | -7.95 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 9.8 Million | - | 9.8 Million | 4.14 Million |
| Other Investing Activities | -4.96 Million | - | 3.65 Million | 11 Thousand | 9000.00 | -228 Thousand |
| Financing Cash Flow | -4.18 Million | -764 Thousand | -3.03 Million | -756 Thousand | -753 Thousand | 10.9 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 13.77 Million |
| Other Financing Activities | -4.18 Million | - | - | - | - | - |
| Accounts receivables | -7.14 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -2.59 Million | -1.67 Million | -2.58 Million | -1.45 Million | -2.17 Million | -2.88 Million |
| Other working capital | 3.23 Million | - | - | - | - | - |
| Cash at beginning of period | 132.74 Million | 116.87 Million | 89.41 Million | 87.14 Million | 89.41 Million | 70.01 Million |
| Cash at end of period | 136.31 Million | 132.74 Million | 116.87 Million | 90.85 Million | 87.14 Million | 89.41 Million |
| Capital Expenditure | -4.69 Million | -1.78 Million | -9.75 Million | -1.45 Million | -3.28 Million | -7.95 Million |
| Effect of forex changes on cash | 465 Thousand | 2.17 Million | -110 Thousand | 781 Thousand | 275 Thousand | 553 Thousand |
| Net cash flow / Change in cash | 3.56 Million | 15.87 Million | 27.45 Million | 3.7 Million | -2.27 Million | 19.4 Million |
| Free Cash Flow | 7.7 Million | 14.46 Million | 17.14 Million | 3.67 Million | -11.6 Million | 4.02 Million |
JAN
CCRRF
000037
PROF-B
102260
MARKOLINES